A direct radioimmunoassay for the determination of ACTH in a small volume of serum was developed using a commercially available antiserum and tracer. A single-stage radioimmunoassay with an incubation period of 4 days gave reliable and reproducible ACTH values. In the incubation medium 0·1 % 2-mercaptoethanol was used as the antioxidant. During a 15-month period the assay has been used routinely in the laboratory.
A direct radioimmunoassay for the determination of adrenocorticotropic hormone (ACTH) and a clinical evaluation
A direct radioimmunoassay for the determination of ACTH in a small volume of serum was developed using a commercially available antiserum and tracer. A single-stage radioimmunoassay with an incubation period of 4 days gave reliable and reproducible ACTH values. In the incubation medium 0·1 % 2-mercaptoethanol was used as the antioxidant. During a 15-month period the assay has been used routinely in the laboratory.
The coefficient of variation was less than 10% in the physiological and pathological range. A normal range of 12 to 60 ng/L was found. The reliability of the assay is demonstrated by results obtained in patients with disorders of the pituitary-adrenal axis.
ACTH is a polypeptide of 39 amino acids with a molecular weight of about 4500. In a great number of mammalian species the primary structure of the ACTH molecule is identical for the amino acid sequence 1-24 and 33-39. There are only a few differences within the amino acid sequence 25-33.1. 2 The basic amino acid sequence 15-18 plays a role in the binding and affinity to the receptor. whilst the biologically active centre responsible for the stimulation of the corticosteroid production and release by the adrenal cortex is localised in the 5-10 sequencer'
Determination of the ACfH levels in serum or plasma is difficult as a result of the following factors.
(1) The concentration of ACTH in blood of normal subjects is low. with large variation during the day. ' (2) The ACTH molecule is relatively small and tends to adsorb to glass. This adsorption can be diminished by using siliconised glass tubes or polystyrene tubes.
(3) The ACfH molecule degrades easily by proteolytic enzymes present in plasma or serum. Storage of plasma at room temperature for 24 h results in a loss of 5()-l)(J'Yo of the ACfH concentration." (4) The immunoreactivity of the tracer ([ 12"I]ACTH) decreases rapidly due to oxida-tion of the sulphide group of methionine on position 4 of the ACfH molecule.' It can be expected that ACTH in blood or plasma will also be oxidised and that the loss of immunoreactive ACTH in plasma is partly due to this phenomenon.
Until recently' most reliable RIA used for ACfH needed an extraction. The availability of an antibody with high specificity made it possible to develop a direct method for ACfH determination in a small volume of serum or plasma. which is relatively cheap and easy.
We have used the commercially available antiserum and tracer with high specific activity. A second antibody coated to cellulose was used for the separation of the bound and free fraction.
Materials and methods

SOLUTION
The basic RIA buffer consists of 62 mmol disodium hydrogen phosphate and 13 mmol Na2EDTA per litre distilled water (pH=7-4). This solution is kept at 4°C and is freshly prepared every 14 days.
RIA-diluent is freshly prepared by adding to 100 mL of RIA buffer the following compo- 
SEPARATION OF BOUND AND FREE
FRACTIONS
For the separation of the antibody-bound and free fraction we used a donkey anti-rabbit antibody-coated cellulose (Sac-eel) from Wellcome Reagents Ltd (Beckenham, England). According to the manufacturer 100 J.lL Sac-eel is used for the separation. The addition of more Sac-eel resulted in a higher percentage of non-specific binding without giving a higher bound fraction. The bound fraction is stable after an incubation time between 10 min and 3 h Health, Bethesda, USA) is stored in 0·2 mL portions containing 10 000 pg ACTH each. Before use 0·8 mL RIA-diluent or 0·8 mL ACTH-free serum is added to one portion and diluted further with RIA-diluent or with ACfH-free serum to concentrations of 5 to 1000 pg hACfH per mL. The cross-reactivity was determined with the following peptides, which were gifts of Dr J M van Ree, Rudolf Magnus Institute for Pharmacology, Utrecht, The Netherlands: ACfH 1-24, I-10, 1-16, 4-10,4-16 NH" 5-16 Nil" pACTH, rACTH and u-MSH.~-Endorphin was purchased from UCB-Bioproducts (Brussels, Belgium). Before assay one portion is purified by means of chromatography, using 0·9 x 60 ern Sephadex G 50 (fine) plastic columns (Pharmacia Fine Chemicals, Uppsala, Sweden) with RIA-diluent as the eluent. The chromatograms show three peaks of 125 1: damaged [ 1251]ACTH bound to albumin and/or 1251-large molecular weight ACTH in the void volume; P 25 1]ACfH in the middle peak; and free 125 1 in the total volume. The percentage of the total radioactivity found in the three peaks is 2·5 ± 1·1% for the void volume; 90·2 ± 1·3% for the middle peak; and 6·9 ± 1·0% for the total volume. Significant differences were not found in these percentages when a 2-week-old (fresh) tracer or a 6-week-old tracer was purified by means of the column chromatography.
The middle peak is used as the tracer in the assay (Fig. 1 ). In the assay 2000 cpm (3---5 pg ACfH) are added to each tube. STANDARDS Synthetic hACfH I -3 'J (National Institute of ANTISERUM The commercially available anti-ACfH serum raised in rabbit from IgG Corporation (Nashville, USA) is directed against the amino acid sequence 5-18 of the ACfH molecule. To the contents of one vial (10 J.lL lyophilized rabbit anti-ACfH serum) 1 mL of RIA buffer containing 0·25% (w/v) BSA was added. The resulting 1:100 dilution was stored in 0·1 mL portions in polystyrene tubes at -20°C.
In order to determine the antiserum dilution which would give a BjT of 30-35%, an antibody dilution curve was set up with the antibody dilution ranging from 1:1500 to 1:96000. In agreement with the manufacturer we found an optimal antiserum dilution of 1:30000. land); 0·1% (v/v) Triton X-l00 (Serva, Heidelberg, Germany); 2 mL Trasylol (1o-~Kallikreine Inhibitory Units/lO mUampoule, Bayer, Leverkusen, Germany); and 0·35%' (v/v) 2mercaptoethanol (BioRAD Laboratories, Richmond, California, USA). and therefore we used 30 min, in agreement with the recommendation of the manufacturer.
COLLECTION OF SAMPLES
Blood samples from the patients were collected in plastic or siliconised glass tubes in ice. After coagulation, the blood was centrifuged at 4°C and the serum was stored in plastic tubes at -20°C until assay. ACTH-free serum was obtained from a normal subject at 9.00 h who had taken 1 mg dexamethasone at 21.00 h the evening before. This serum showed undetectable cortisol levels and so we assumed that this serum was ACTH-free.
Procedure
After initial studies to determine optimal conditions, the procedure shown in Table 1 was adopted.
The whole RIA procedure was carried out between 0 and 4°C by performing all procedures in ice-water baths. The tubes were mixed and incubated for 4 days at 4°C. At the end of this period 100 ul, Sac-eel was added followed by incubations for another 30 min, after which 1 mL distilled water was added to each tube. The tubes were centrifuged at 2500 g for 20 min (4°C) and the supernatant was aspirated carefully and discarded. The radioactivity of the totals and the pellets was counted with a Direct RIA for ACTH 249 gamma-spectrometer (Packard Auto-Gammascintillation spectometer 510, USA) for 10 min.
The final procedure used for the direct estimation of ACTH is similar to the one recently described by Nicholson et al., 5 except for the following differences: we used 2mercaptoethanol in the diluent, we incubated for 4 days and used a single-stage assay. The standards were diluted in RIA-diluent, containing 0·25% BSA (w/v). A commercially available [ 125I]pACTH was used as the tracer. The bound and free fractions were separated by means of Sac-eel.
Results
THE USE OF 2-MERCAPTOETHANOL IN THE
BUFFER
Before using 2-mercaptoethanol in the RIAdiluent we found high non-specific binding (blanks) of about 10%. After adding 0-35% (v/v) 2-mercaptoethanol to the diluent, the blanks were found to be lower than 5%. In Table 2 the influence of 2-mercaptoethanol on the blanks of RIA-diluent and of serum after different incubation periods is given.
Experimental variations in the concentration of 2-mercaptoethanol between 0·1 and 0·5% caused no increase of the blanks at the lower concentrations. We decided therefore to use 0·35% 2-mercaptoethanol only in RIA-diluent Blood from a patient who had been subjected to bilateral adrenalectomy. who had an ACTH concentration of about 1000 ng/L, was collected into heparin tubes. The blood of this patient was kept under different circumstances and at regular intervals a specimen of the plasma was frozen at -20°C. The IR-ACTH showed similar losses: 20% was lost after 5 hand 70% was lost after 24 h when stored at room temperature; when the blood was kept in ice immediately and stored at 4°C, the IR-ACTH was stable during 250 Arts et al.
in which the tracer was diluted. The end concentration of the antioxidant in the final incubation tubes for ACTH determination was about 0·1%. STANDARD 
DILUTION
In RIA the standard samples should have a composition very similar to the patients' material. It is however laborious to get ACTH-free serum or plasma, and we therefore diluted the standards in RIA-diluent. Using the composition of the RIA-diluent described above the ACTH standard responds similarly when diluted in this RIA-diluent and in ACTH-free serum. Furthermore there is a high degree of parallelism when different patient samples are diluted with RIA-diluent and are compared with the standard curves (Figs 2 and 3) . It is very important to use the right blanks for the RIA-diluent dilutions or the serum dilutions. The specificity of the anti-ACTH antibody was determined by testing several ACTH fragments and related peptides ( Table 3) . Percentage cross-reactivities were calculated from the concentrations (mol/mol) of peptides at 50% displacement of WI-labelled ACTH.
P<;l ACTH added values for the three sera were found in 15 assays: Serum 1: 199±12 (6%) ng/L Serum 2: 43±1O (23%) ng/L Serum 3: 19±6 (33%) ng/L We calculated a precision profile from duplicates of routine analysis obtained over a period of about 6 months ( Fig. 4) . RECOVERY To five different sera synthetic hACfH l -39 was added in concentrations of 50, 100, 200, and 300 pglmL and the ACfH concentration was measured in five-fold. The results (Fig. 5 ) demonstrate a nearly quantitative recovery of the added ACfH.
Clinical evaluation of the ACTH assay REFERENCE VALUES At different times blood was taken from 117 blood-bank donors, who were believed to be free of any known endocrine disorder. The ACTH levels found in these sera are shown in Table 4 . From these results reference values of the ACfH can be calculated. The levels ranged from 18 to 66 ng/L in the morning (about 10.00 h), from 15 to 71 ng/L in the afternoon (about 15.00 h), from 12 to 48 ng/L in the evening (about 20.00 h) and from 13 to 29 ngIL at midnight (Fig. 6 ).
Basal levels of ACfH in blood can be suppressed by the administration of dexamethasone. Undetectable levels were found in the morning samples following the administration of 1 mg dexamethasone at 23.00 h the previous evening (Fig. 6) .
The diurnal rhythm of four patients with pituitary-dependent Cushing's syndrome (Cushing's disease) is shown in Fig. 7A . No circadian rhythm of ACTH was found; the In three patients with Cushing's syndrome a final diagnosis of Cushing's disease was established with these tests. We found a stimulation of ACTH and cortisol with L VP (Fig. 8A and Table 5 ) and suppression of ACfH and cortisol during high-dose dexamethasone infusion (Fig.  8B ). In these three patients with Cushing's disease in whom pre-operatively LVP elicited a distinct ACfH response, the clinical features of Cushing's disease completely disappeared after transphenoidal surgery; ACTH levels were undetectable basally and after L VP stimulation ( Table 5 ). In six patients with Cushing's disease, who were treated by bilateral adrenalectomy, no circadian rhythm of ACfH was found. The levels ranged from 70 to 500 ng/L (Fig. 7B ). Some patients with Cushing's disease with bilateral adrenalectomy eventually develop Nelson's syndrome, a condition characterised by progressive hyperpigmentation of the skin and radiologic evidence of an expanding (ACfH producing) pituitary tumour.f III In one patient with the clinical features of Nelson's Before After Before After Before After 30 min' 0·67  36  0·05  <10  <0·01  <10  0·39  14  0  0·69  40  0·04  <10  0·42  22  <0·01  <10  0·25  15  0·03  <10  30  1·07  116  0·05  <10  0·63  24  0·01  <10  0·70  24  0·07  <10  60  1·14  47  0·17  <10  0·65  32  0·02  <10  0·48  13 0·06 <10
C=the concentration in serum of cortisor" in I1moUL. A=the concentration in serum of ACfH in nglL. 6 o 500 ., In one patient with Addison's disease we found an ACTH level of 1200 ng/L, cortisol 0·01 umol/L, After substitution therapy with cortisone-acetate and 9a-fludrocortisone these values normalised: ACTH 36 ngiL and cortisol 0-45 urnol/L. syndrome we found very high ACTH levels (Fig. 7C) .
The anticonvulsant sodium valproate, a GABA-transaminase inhibitor, has been shown to induce a decrease of plasma ACTH levels in Nelson's syndrome both during chronic treatment and in acute experiments. 1 I. 12 Recently we described a patient with Cushing's disease who did respond to sodium valproate.I'' In some patients with Cushing's disease treated by bilateral adrenalectomy we found a suppression of ACTH by sodium valproate administration ( Fig. 9 ).
We 'admini~tered synthetic corticotrophinreleasing hormone (CRH) (UCB-Bioproducts Brussels, Belgium) to a patient with clinical and biochemical evidence of active Cushing's disease who was previously treated by transphenoidal surgery and pituitary irradiation. The CRH test was performed at 8.00 h after an overnight fast. One hundred !Jog CRH were given as a single i.v. bolus. Blood samples were obtained at intervals shown in Fig. 10 . A distinct ACfH and cortisol response was obtained (Fig. 10) .
In two sisters with Cushing's syndrome the final diagnosis of 'familial Cushing's syndrome due to nodular adrenal dysplasia'!" was based on the absence of an unilateral adrenal mass by CAT-scan analysis and non-detectable plasma ACTH levels. This diagnosis was correct as shown by the findings of the pathologist after surgical removal of the adrenal glands. 
Discussion
In agreement with the recent observations of Nicholson et al. 5 we are able to measure the ACTH concentration directly in a small volume of serum by means of a radioimmunoassay. F~r this purpose a commercially available antiserum with very high specificity for human and other mammalian ACTH molecules was used ( Table 3 ). This antiserum shows no crossreactivity (mol/mol) with ACTH 4-10, ACTH 1-10 (Table 3 ) and other related peptides." It does react with the ACTH fragments 1-24 (138%), 4-16 N H , (21%) and 1-16~21%).
In contrast with the method of NIcholson et al. we used a single-stage method with an incubation time of 4 days, resulting in a sensitivity of 1 pg/tube (10 ng/L) and~n acceptable precision profile (Fig. 4) . A vanation of less than 10% between duplicates was found in the range 30-240 ng/L, the range of interest in normal and pathological studies in human endocrinology.
The immunological reactivity of the ACfH molecule appears to be decreased by oxidation of methionine on position 4 of the molecule. This can be prevented by using 2mercaptoethanol in the medium (Table 2) . Furthermore, 2-mercaptoethanol protects the ACTH molecule against proteolytic enzymes which contain disulphide groups."
Small differences in NSB between serum samples and RIA-diluent (Table~) can. be explained by the fact that there IS possible non-specific binding of tracer to serum proteins.
The lability of ACfH caused by enzyme reactions is partly dependent on the substrate (ACTH) concentration, as is shown by our experiments. At a concentration of 50000 ng/L an incubation period of 1 h at room temperature resulted in a loss of ACTH of 50%. An ACfH concentration of 1200 ng/L needed a 16 h incubation at room temperature for a comparable loss. The IR-ACTH in blood ren:ained stable during 10 h at 4°C; after addition of Trasylol no losses were observed over 24 h at 4°C.
Purification of the tracer prior to each assay will give a higher specific activity of the [ 125 I]A CfH of about 10% (Fig. 1) . ,!,his r~sults in diminished blanks and probably III a higher sensitivity.
The standards were dissolved in RIA-diluent, a phosphate/EDTA buffer pH 7·4 w~i~h contained 0·25% BSA. With this composition the Direct RIA for ACTH 255 same results were obtained as when the standards were dissolved in ACTH-free serum (Fig.  3 ). Furthermore, dilution curves of different sera show a high degree of parallelism with the standard curves (Fig. 2) . Experiments designed to test different concentrations of BSA in the RIA-diluent have indicated that 0·25% BSA was the optimal concentration for this ACfHassay (results not shown).
A reference range of ACfH was established by using sera from blood-bank donors of 12~0 ng/L. These values are in good agreement with the findings of Berson and Yalow, who found values up to 50 ng ACTH per litre in normal subjects.i'
With the method described, ACTH has been measured in large numbers of normal subjects and of patients suspected for diseases of the pituitary-adrenal axis over a period of 15 months. In agreement with early observations': 15 we found a decrease of ACTH after dexamethasone administration to undetectable values in normal subjects (Fig. 6 ). More recently Fang et al. 16 were still able to measure ACTH after suppression. However, it is more likely that these results are possibly due to a non-specific determination for ACfH.
In the section 'Clinical evaluation of the ACfH assay' we showed that no circadian rhythm was seen in four patients with Cushing's disease. The levels ranged from 30 to 200 ng/L (Fig. 7A ). Six patients with Cushing's disease who were treated by bilateral adrenalectomy also did not show a diurnal rhythm of ACTH and these levels ranged from 70 to 500 ng/L (Fig. 7B ). These higher levels can be explained by loss of the negative feedback regulation after surgery. The completeness of hypophysectomy can be evaluated by measuring basal ACTH levels and ACfH levels after stimulation with LVP pre-and post-operatively (Table 4 ). High to extremely high ACfH concentrations are found in patients with Nelson's syndrome!" (Fig. 7C) .
We also performed a CRH test (100 ug as an i.v. bolus) in a patient with Cushing's disease; in agreement with the recent findings of others 1 K--20 we found a clear response of ACfH and cortisol.
